Yonhap Infomax NewsNov 5
SK Biopharmaceuticals Co. reported a 262.4% year-on-year surge in Q3 operating profit, driven by robust Xcopri sales and cost efficiencies, far surpassing market expectations.
#YonhapInfomax #SKBiopharmaceuticals #Xcopri #OperatingProfit #Q3Results #EpilepsyDrugSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89254
SK Biopharmaceuticals Q3 Operating Profit Surges 262.4% on Robust Xcopri Sales (Comprehensive)

SK Biopharmaceuticals Co. reported a 262.4% year-on-year surge in Q3 operating profit, driven by robust Xcopri sales and cost efficiencies, far surpassing market expectations.

Yonhap Infomax